Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.
Company Details
- Employees
- 57
- Founded
- -
- Address
- 70, Rue Saint-Jean-De-Dieu, Lyon,auvergne-Rhône-Alpes 69007,france
- Phone
- +33 4 37 65 55 03
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- osivax.com
- Keywords
- biotechnology, immunology, antigens, vaccine, Influenza, universal, cellular immune response, CD8 T-cell, Infectious diseases, Immuno-oncology, covid.
- HQ
- Lyon, Auvergne-Rhône-Alpes
Osivax Questions
Osivax's helpline number is +33 4 37 65 55 03
Osivax's website is osivax.com
Osivax's LinkedIn profile is https://fr.linkedin.com/company/osivax
Osivax has
57 employees.
View email and phone details for 57
employees at Osivax.
Osivax's industry is
Biotechnology Research
Osivax's top competitors are
Adocia,
Abivax,
Nosopharm,
Genoway,
Innate Pharma,
Bioaster,
Fabentech,
Enyo Pharma,
Maat Pharma,
Phaxiam Therapeutics.
Osivax's categories are Biotechnology Research
Osivax's founding year is 2017
